Lagardère S.A. : Short-term turn-around to the downside ahead
Entry price | Target | Stop-loss | Potential |
---|
€22.43 |
€21 |
€23.4 |
+6.35% |
---|
Shares in Lagard?re have recently experienced substantial gains. This suggests that the timing is opportune to lock in gains prior to a likely technical correction.
Strengths● The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.6 for the 2016 fiscal year.
● The company is one of the best yield companies with high dividend expectations.
Weaknesses● Stock prices approach a strong long-term resistance in weekly data at EUR 23.33.
● According to Thomson-Reuters' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
● Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
● For the last four months, EPS estimates made by Thomson-Reuters analysts have been revised downwards.
● For the past year, analysts have significantly revised downwards their profit estimates.
● The underlying tendency is negative on the weekly chart below the resistance at 23.33 EUR
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.